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Is depression or polypharmacy at work? 
As the population ages, primary care 
physicians encounter a signifi cant number 
of patients with memory loss and dementia. 
In clinical practice, patients with subjective 
memory complaints but normal cognitive 
testing present a diagnostic dilemma. 
Close attention to comorbid psychiatric 
conditions such as depression, anxiety, 
and substance use disorders, as well as 
polypharmacy, is essential. 
 While the US Preventive Services 
Task Force indicates that there is 
insuffi cient evidence to screen, it notes 
that recognizing cognitive impairment 
early not only facilitates diagnostic and 
treatment decisions, but also allows 
clinicians to anticipate problems the patient 
may have in understanding and adhering 
to recommended therapy. Even though 
evidence of early or minimal dementia may 
be diffi cult to detect, identifying it promptly 
enables physicians to counsel patients 
and caregivers on the course of disease 
progression, warning signs, medication 
adherence, fi nances, and safety.
Rajasree Nair, MD
Baylor College of Medicine, Houston, Tex
Clinical commentary
Depression, anxiety, and dementia, as 
well as older age, female gender, lower 
education level, and decreased physical 
activity, have all been associated with 
memory loss reported by patients or family 
members (strength of recommendation 
[SOR]: B, cross-sectional studies). Memory 
complaints in patients with no cognitive 
impairment on short cognitive screening 
tests, such as the mini-mental status exam, 
may predict dementia (SOR: B, longitudinal 
studies). No consistent evidence supports 
pharmacologic treatment of reported 
memory loss that is not corroborated by 
objective fi ndings (SOR: B, nonrandomized, 
poor-quality studies).  
Evidence-based answer
What could be behind your 
elderly patient’s subjective 
memory complaints? 
❚ Evidence Summary
Several cross-sectional studies indicate 
that patients with subjective memory loss 
are more likely to be older, female, less 
physically active, in poorer health, less 
educated, and more depressed or anxious 
than unaffected patients.1-4 These studies 
concentrate mostly on elderly people liv-
ing in the community. 
A study of 1883 patients with normal 
baseline short-cognitive test results found 
that those with subjective memory com-
plaints had a higher incidence of demen-
tia.5 At 5-year follow-up, 15% of patients 
with baseline subjective memory com-
plaints had developed dementia compared 
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to only 6% of those without such com-
plaints (odds ratio=2.7; 95% confi dence 
interval [CI], 1.45-4.98). 
A prospective cohort study that fol-
lowed 158 patients with no evidence of 
dementia showed a signifi cant correla-
tion between informant-reported memory 
problems and development of dementia 
at 5 years.6 Forty-fi ve percent of patients 
with informant-reported memory prob-
lems developed dementia after 5 years 
compared with 25% of patients who had 
only self-reported memory problems (P 
=.02). This result suggests that subjective 
memory problems reported by observers 
(family or caregivers) may be more predic-
tive of dementia than self-reported memo-
ry complaints.
Donepezil, ginkgo biloba 
may not help these patients
Most trials of interventions to preserve 
memory have not enrolled patients with 
subjective memory complaints. How-
ever, data from trials that enrolled either 
asymptomatic elderly patients or patients 
with mild cognitive impairment don’t sup-
port the use of donepezil, ginkgo biloba, 
NSAIDs, COX-2 inhibitors, vitamin E, vi-
tamin B6, vitamin B12, statins, hormone re-
placement therapy, or omega-3 fatty acids 
to delay progression to dementia.7-16 
Could mental exercise help?
One systematic review of 22 longitudi-
nal cohort studies, which included more 
than 29,000 patients, evaluated complex 
patterns of mental activity in early, mid-, 
and late-life in relation to the incidence 
of dementia. Dementia was diagnosed at 
a signifi cantly lower rate in patients with 
a higher level of cognitive exercise, such 
as memory-based leisure activities and 
social interactions, than those with less 
rigorous daily cognitive challenges (rela-
tive risk=0.54; 95% CI, 0.49-0.59).17 
This raises the possibility that mental 
exercise has neuroprotective effects. No 
randomized trials exist to support this hy-
pothesis, however.  
Recommendations
There is no consensus regarding the no-
menclature applied to reported memory 
loss and mild cognitive impairment. The 
Clinical Manual of Geriatric Psychiatry 
provides defi nitions that can be used in 
the clinical setting (TABLE).18
The US Preventive Services Task Force 
concludes that evidence is insuffi cient to 
recommend for or against routine screen-
ing for dementia in older adults (I recom-
mendation).19 However, the Task Force 
notes that clinicians should assess cogni-
tive function whenever they suspect im-
pairment or deterioration based on direct 
observation, patient report, or concerns 
raised by family members, friends, or care-
takers.  
The American Geriatrics Society20 and 
American Academy of Neurology (AAN)21 
acknowledge the subtle difference between 
age-associated memory impairment and 
mild cognitive impairment, and the diffi -
culty of differentiating normal changes of 
No consistent 
evidence supports 
drug treatment 
of reported 
memory loss 
that is not 
corroborated by 
objective ﬁ ndings 
Features of age-associated memory 
impairment vs mild cognitive impairment
FEATURE
AGE-ASSOCIATED 
MEMORY IMPAIRMENT 
MILD COGNITIVE 
IMPAIRMENT
Clinical 
presentation
•  ≥50 years of age 
with reported memory 
complaint (40% of 
people in their 50s and 
85% of people ≥80 
years of age)
• Normal mental status
•  Intact ADLs and IADLs 
•  Reported memory 
complaint or memory 
problems noted by an 
informant
•  Learning and recall most 
often affected
• Normal mental status
•  Intact ADLs and subtle 
changes in IADLs (such 
as managing fi nances)
Memory test 
results
•  Within 1 SD of the av-
erage level for young 
adults on a standard-
ized memory test
•  More than 1.5 SD below 
the average level for age 
peers on a standardized 
memory test
Clinical course •  Generally stable for 
periods of at least 
4 years
•  Progresses to dementia 
at the rate of 10% to 12% 
per year; some patients 
remain free of dementia 
for at least 10 years
ADLs, activities of daily living; IADLs, instrumental activities of daily living; 
SD, standard deviation. 
Source: Spar JE, La Rue A. Clinical Manual of Geriatric Psychiatry.18 
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aging from abnormal changes. The AAN’s guidelines for 
early detection of dementia emphasize the importance of 
diagnosing mild cognitive impairment or dementia early. 
However, the guidelines specifi cally exclude patients with 
subjective memory loss unaccompanied by objective cog-
nitive defi cits and offer no further discussion about these 
patients. ■
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